Adam Novak - Ascom Holding Head Excellence
| ASCN Stock | CHF 5.39 0.09 1.70% |
Executive
Adam Novak is Head Excellence of Ascom Holding AG
| Address | Zugerstrasse 32, Baar, Switzerland, 6340 |
| Phone | 41 41 544 78 00 |
| Web | https://www.ascom.com |
Ascom Holding Management Efficiency
The company has return on total asset (ROA) of 0.0275 % which means that it generated a profit of $0.0275 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of 0.0412 %, meaning that it generated $0.0412 on every $100 dollars invested by stockholders. Ascom Holding's management efficiency ratios could be used to measure how well Ascom Holding manages its routine affairs as well as how well it operates its assets and liabilities. At this time, Ascom Holding's Return On Tangible Assets are fairly stable compared to the past year. Return On Capital Employed is likely to climb to 0.1 in 2026, whereas Return On Assets are likely to drop 0.02 in 2026. At this time, Ascom Holding's Non Currrent Assets Other are fairly stable compared to the past year. Intangible Assets is likely to climb to about 48.7 M in 2026, whereas Non Current Assets Total are likely to drop slightly above 101.9 M in 2026.Similar Executives
| Showing other executives | EXECUTIVE Age | ||
| Catherine ACMA | Santhera Pharmaceuticals Holdin | 51 | |
| David Maso | DocMorris AG | 55 | |
| Martin Schlter | Coltene Holding AG | 54 | |
| Dominik Arnold | Coltene Holding AG | 54 | |
| Martin Steegmaier | Molecular Partners AG | N/A | |
| Laura Faravelli | Newron Pharmaceuticals SpA | N/A | |
| Renate Gloggner | Molecular Partners AG | 56 | |
| David Arnon | S H L | 56 | |
| Filippo Moriggia | Newron Pharmaceuticals SpA | N/A | |
| Oliver Strub | Santhera Pharmaceuticals Holdin | 63 | |
| Gregor Picard | Coltene Holding AG | 56 | |
| Ravi MD | Newron Pharmaceuticals SpA | 69 | |
| Paul Frey | Coltene Holding AG | 51 | |
| Robert Hendriks | Molecular Partners AG | N/A | |
| Roberto Galli | Newron Pharmaceuticals SpA | N/A | |
| Oliver Kronenberg | Santhera Pharmaceuticals Holdin | 58 | |
| Luc Gruner | Evolva Holding SA | 74 | |
| Di Hu | Coltene Holding AG | 49 | |
| Astrid Schafer | Evolva Holding SA | 53 | |
| Pamela Trail | Molecular Partners AG | 70 | |
| Sarah HolmesKlotz | Santhera Pharmaceuticals Holdin | N/A | |
Management Performance
| Return On Equity | 0.0412 | ||||
| Return On Asset | 0.0275 |
Ascom Holding AG Leadership Team
Elected by the shareholders, the Ascom Holding's board of directors comprises two types of representatives: Ascom Holding inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Ascom. The board's role is to monitor Ascom Holding's management team and ensure that shareholders' interests are well served. Ascom Holding's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Ascom Holding's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Daniel Lack, Communications Legal | ||
| Konstantinos Nikolopoulos, Head Marketing | ||
| Tobias Stanelle, Managing Canada | ||
| Kelly Feist, Managing Canada | ||
| Brigitte Spolenak, Chief Officer | ||
| Nicolas Abeele, CEO Board | ||
| Yves Joens, Head Solutions | ||
| Job Kamphuis, Managing North | ||
| Valerio Signorelli, Managing DACH | ||
| Jens Andersen, Managing Nordics | ||
| Gaby Hunziker, Chief Officer | ||
| Dominik Maurer, CFO Board | ||
| Guido Gloy, Managing South | ||
| Adam Novak, Head Excellence | ||
| Michael Reitermann, Interim Director | ||
| Kalina Scott, Chief Officer | ||
| Christophe Scheidegger, General Operations | ||
| Paul Lawrence, Managing UK | ||
| Olaf Hendriks, Managing Netherlands |
Ascom Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Ascom Holding a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | 0.0412 | ||||
| Return On Asset | 0.0275 | ||||
| Profit Margin | 0.01 % | ||||
| Operating Margin | 0.04 % | ||||
| Current Valuation | 171.36 M | ||||
| Shares Outstanding | 35.92 M | ||||
| Shares Owned By Insiders | 1.21 % | ||||
| Shares Owned By Institutions | 51.82 % | ||||
| Price To Earning | 21.86 X | ||||
| Price To Book | 2.62 X |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for Ascom Stock Analysis
When running Ascom Holding's price analysis, check to measure Ascom Holding's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Ascom Holding is operating at the current time. Most of Ascom Holding's value examination focuses on studying past and present price action to predict the probability of Ascom Holding's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Ascom Holding's price. Additionally, you may evaluate how the addition of Ascom Holding to your portfolios can decrease your overall portfolio volatility.